Around two million Americans have moderate to severe plaque psoriasis, an autoimmune condition that causes dry, itchy, scaly patches (or plaques) to form across the skin.

Thanks to new findings, there’s a significant improvement in curing moderate to severe scalp psoriasis.

A first-of-its-kind study 100% dedicated to people of color living with moderate to severe plaque psoriasis (PsO) is redefining representation in clinical research and helping to bridge critical ...

Tildrakizumab was well tolerated and achieved sustained response in patients with moderate to severe plaque psoriasis of the scalp in a phase 3 study. This study excluded patients with ...

Tremfya demonstrated greater treatment persistence than interleukin-17 inhibitors in patients with moderate to severe plaque psoriasis and achieved clinical efficacy in scalp psoriasis, according ...

The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp ...

Deucravacitinib proved to be efficacious in the treatment of moderate to severe scalp psoriasis and less extensive overall psoriasis, according to two presentations at the European Academy of ...

84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 ICONIC-LEAD is the first ever Phase 3 ...

Guselkumab (Tremfya) showed rapid and significant clearance in patients of color with moderate-to-severe scalp psoriasis, as well as significant improvement in scalp itch and patient-reported ...

After being diagnosed with moderate to severe plaque psoriasis, this life coach learned how to feel comfortable in her skin again.

This study was the first to evaluate systemic pharmacotherapy for scalp psoriasis in which participants were not required to also have moderate-to-severe body plaque psoriasis.